Transfusion Medicine最新文献_第4页

Intravenous immunoglobulin weaning evaluation with zero-shot large language model classification. 用零针大语言模型分类评价静脉免疫球蛋白断奶。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-11-05 DOI: 10.1111/tme.70020

Emily Burton, Shrirajh Satheakeerthy, Rudy Goh, Brandon Stretton, Andrew E C Booth, Christina Gao, Nivida Dixit, Sarah Howson, Shaun Evans, Oliver Kleinig, Joe Lu, Joshua Kovoor, Aashray Gupta, Weng Onn Chan, Andrew Zannettino, Keith McNeil, Chantal Baldwin, Wilson Vallat, John Maddison, Samuel Gluck, James Triplett, Toby Gilbert, Stephen Bacchi

{"title":"Intravenous immunoglobulin weaning evaluation with zero-shot large language model classification.","authors":"Emily Burton, Shrirajh Satheakeerthy, Rudy Goh, Brandon Stretton, Andrew E C Booth, Christina Gao, Nivida Dixit, Sarah Howson, Shaun Evans, Oliver Kleinig, Joe Lu, Joshua Kovoor, Aashray Gupta, Weng Onn Chan, Andrew Zannettino, Keith McNeil, Chantal Baldwin, Wilson Vallat, John Maddison, Samuel Gluck, James Triplett, Toby Gilbert, Stephen Bacchi","doi":"10.1111/tme.70020","DOIUrl":"10.1111/tme.70020","url":null,"abstract":"Objectives: The aims of this study were to determine the performance of a large language model (LLM) with a zero-shot strategy for the classification of several factors relevant to the consideration of intravenous immunoglobulin (IVIg) weaning.Background: In many cases, IVIg should be weaned to prevent excessive resource utilisation and adverse effects.Methods and materials: A cohort study was conducted examining neurology outpatients receiving regular IVIg in a 2-month period. Prespecified criteria were used to determine how many individuals were suitable for IVIg weaning. A LLM was applied to determine the level of performance with which the model could provide answers to the prespecified criteria.Results: In the inclusion period, 14 individuals were identified and four patients fulfilled the criteria for possible IVIg weaning. The total annual cost saving with IVIg weaning was conservatively estimated to be $84702.20 (1433.9 g of IVIg annually). The LLM achieved an overall classification accuracy of 78.6% (11/14) when a rule-based approach was applied to the individual criteria that it extracted from notes.Conclusion: Further research is indicated to determine the frequency with which patients suitable for IVIg weaning are identified at other centres and the degree to which LLM may be able to assist with this process.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"79-83"},"PeriodicalIF":1.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improvising neonatal thrombocytopenia management: Insights from split, volume-reduced, single-donor apheresis platelets (NeoVRs-SDAP). 新生儿血小板减少症的临时管理：从分裂，体积减少，单供体单采血小板（NeoVRs-SDAP）的见解。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-11-19 DOI: 10.1111/tme.70024

Yashaswi Dhiman, Saikat Patra, Chinmay Chetan, Manish Raturi, Shoham Majumder, Rolika Nautiyal, Tushar Bhardwaj, Dushyant Singh Gaur

{"title":"Improvising neonatal thrombocytopenia management: Insights from split, volume-reduced, single-donor apheresis platelets (NeoVRs-SDAP).","authors":"Yashaswi Dhiman, Saikat Patra, Chinmay Chetan, Manish Raturi, Shoham Majumder, Rolika Nautiyal, Tushar Bhardwaj, Dushyant Singh Gaur","doi":"10.1111/tme.70024","DOIUrl":"10.1111/tme.70024","url":null,"abstract":"Introduction: Thrombocytopenia is common in neonates, managed with platelet transfusions at defined dose. The product type varies from neonatal-specific units using platelet additive solutions to adult products split into multiple paediatric units. In low-middle-income countries, whole blood-derived random donor platelets (RDP) are common while western countries use split adult single donor apheresis platelets (SDAP). We aimed to assess preliminary effectiveness of split, volume-reduced single donor apheresis platelets (NeoVRs-SDAP) in neonatal thrombocytopenia and observe early post-transfusion outcomes.Methods: Study was conducted from August 2024 to January 2025 at a tertiary healthcare centre. Persistent thrombocytopenic neonates admitted to the NICU were transfused with NeoVRs-SDAP prepared using Spectra Optia® with modified program yielding an adult dose (300 × 109) in a reduced 100 mL of product volume. These were split into 2-5 aliquots for transfusion. Post-transfusion platelet increments and percentage recovery were assessed after 20-24 h.Results: Thirteen neonates' 77% preterm, 69.2% VLBW with sepsis received 46 NeoVRs-SDAP. 10 mL of this product contained nearly 3 times more platelets than RDP and 1.5 times more than adult SDAP of same volume. The mean transfused dose was 70.56 ± 14.21 × 109 platelets. Median platelet increment was 64 500/μL versus 15 477/μL for RDP (p < 0.001). Platelet recovery ranged from 7.5%-52.5%. Split products reduced donor exposure by 56.5%. Survival was 62%, without any transfusion-related adverse events.Conclusion: NeoVRs-SDAP may be potential alternative in persistent neonatal thrombocytopenia, offering better increments and recovery, reduced donor exposure, and leukoreduction. Further RCTs comparing NeoVRs-SDAP and RDP are recommended.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"72-78"},"PeriodicalIF":1.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145551010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A framework checklist for implementing bedside electronic transfusion systems. 实施床边电子输液系统的框架检查表。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-11-14 DOI: 10.1111/tme.70042

Josephine McCullagh, Suzanne Makki, Kirsty Hancock, Catherine Booth, Louise Bowles, Ollie Djurdjevic, Karen Farrar, Claudio Geraci, Sara Hammond, Helinor Mcaleese, Michael F Murphy, Florence Oyekan, Laura Green

{"title":"A framework checklist for implementing bedside electronic transfusion systems.","authors":"Josephine McCullagh, Suzanne Makki, Kirsty Hancock, Catherine Booth, Louise Bowles, Ollie Djurdjevic, Karen Farrar, Claudio Geraci, Sara Hammond, Helinor Mcaleese, Michael F Murphy, Florence Oyekan, Laura Green","doi":"10.1111/tme.70042","DOIUrl":"10.1111/tme.70042","url":null,"abstract":"Background: Every time a unit of blood is given to a patient, it is essential that all steps in the transfusion pathway are executed correctly to ensure that the right blood is transfused to the right patient. Bedside transfusion checks at the point of sampling for compatibility testing, sample labelling and blood administration are an essential part of the delivery of safe transfusion and avoidance of the wrong blood being given, which can have serious consequences. Implementation of bedside electronic transfusion systems that use barcode matching of patients' wristbands and blood units is now recommended as the best practice to ensure patients' safety in transfusion. However, there is limited information in the literature to guide hospitals on what aspects they should consider when introducing a bedside electronic transfusion system.Aims and methods: This paper aims to support hospitals considering implementing a bedside electronic transfusion system by providing a comprehensive checklist addressing planning, stakeholder coordination, device integration, and compliance with national standards and safety requirements.Results: The checklist is based on the experiences of two NHS Trusts in the UK and aims to provide organisations with a resource to support this change and reduce avoidable delays.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"3-9"},"PeriodicalIF":1.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145523906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zika virus surveillance post-epidemic in blood donors from São Paulo, Brazil 2016-2020. 2016-2020年巴西<s:1>圣保罗献血者流行后寨卡病毒监测。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-10-16 DOI: 10.1111/tme.70030

Suzete Cleusa Ferreira, José Eduardo Levi, Anna Shoko Nishiya, Cesar de Almeida-Neto, Jerenice Esdras Ferreira, Juliana Derriga, Nanci A Salles, Silvia Petrossi Gallo Polato, Katia C Dantas, Edmir Boturão-Neto, Martha Mathias Rocha, Vanderson Rocha, Alfredo Mendrone-Jr

{"title":"Zika virus surveillance post-epidemic in blood donors from São Paulo, Brazil 2016-2020.","authors":"Suzete Cleusa Ferreira, José Eduardo Levi, Anna Shoko Nishiya, Cesar de Almeida-Neto, Jerenice Esdras Ferreira, Juliana Derriga, Nanci A Salles, Silvia Petrossi Gallo Polato, Katia C Dantas, Edmir Boturão-Neto, Martha Mathias Rocha, Vanderson Rocha, Alfredo Mendrone-Jr","doi":"10.1111/tme.70030","DOIUrl":"10.1111/tme.70030","url":null,"abstract":"Introduction: Zika virus (ZIKV) is primarily transmitted through the bite of the Aedes aegypti mosquito, though transmission via blood transfusion has also been documented. During the 2015 ZIKV epidemic in Brazil, severe complications were observed in pregnant women, leading to fetal microcephaly. This study evaluated the persistence of ZIKV in blood donated by healthy individuals during the post-epidemic period from 2016 to 2020.Methods: Blood donor samples from 109 296 individuals were screened for ZIKV RNA using nucleic acids extracted from plasma pools (six donors per pool). These samples had previously undergone routine nucleic acid testing (NAT) for HBV, HCV and HIV.Results: Viral RNA (Ribonucleic Acid) was detected in a donor sample from the city of Santos in May 2016, resulting in a prevalence of 0.0009%. The positive donor was confirmed through viral sequencing using the Sanger method. Sequencing and phylogenetic analysis of an envelope gene amplicon revealed that the Zika virus RNA detected belonged to the Asian clade. This Asian lineage strain emerged in Brazil, Fortaleza, in 2015, isolated in northeastern Brazil in 2015, an area where most cases of microcephaly associated with ZIKV have been reported. A follow-up sample collected 1 month after donation showed seroconversion.Conclusion: The detection of ZIKV RNA by NAT in a donated blood sample demonstrates that, although extremely rare, the virus is still present. Periodic active surveillance of blood donations for viruses associated with past outbreaks may help identify an incipient resurgence before it develops into a new epidemic.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"59-65"},"PeriodicalIF":1.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of a new solid-phase ABO and RhD blood grouping kit. 一种新型固相ABO和RhD血型分型试剂盒的评价。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-10-12 DOI: 10.1111/tme.70032

Yuelong Xu, Rong Wang, Dongmei Ge, Xingyu Huang, Yuanming Yang, Zifan Meng, Haiyan Wang, Ying Li

{"title":"Evaluation of a new solid-phase ABO and RhD blood grouping kit.","authors":"Yuelong Xu, Rong Wang, Dongmei Ge, Xingyu Huang, Yuanming Yang, Zifan Meng, Haiyan Wang, Ying Li","doi":"10.1111/tme.70032","DOIUrl":"10.1111/tme.70032","url":null,"abstract":"Objectives: Rapid and accurate identification of blood groups is the foundation of emergency blood support. We performed a complete assessment of a new solid-phase kit for ABO forward grouping and RhD grouping (ABD Kit, InTec Products, Xiamen, China) on the analytical performance, which was compared with those of traditional methods.Methods: We analysed 1260 clinical samples using the ABD Kit, including weakly agglutinated samples of A, B and D antigen, and compared the test results with those via Gel card, test tube and slide methods. We also validated the results of typing blood samples containing weak antigens using first-generation gene sequencing.Results: The ABO forward group and RhD group of 1260 samples was determined using ABD Kit, revealing that the inter-batch repeatability rate of the kit was 100%. The results of the kit were compared with those of the gel card method, revealing that the detection accuracy of the kit was also 100%, which was confirmed by comparing the detection of weak antigen samples with the results of first-generation gene sequencing. The accuracy of the test tube agglutination method was 100%. In contrast, the accuracy of the slide agglutination method was low, especially in the detection of weak A blood antigens (agglutination strength 1+), weak B blood antigens (agglutination strength 1+) and weak D blood antigens (agglutination strength 1+ or 2+).Conclusions: The ABD Kit (InTec Products, Xiamen, China) showed high sensitivity, reproducibility and specificity, indicative of excellent analytical performance. It is a reliable, practical and promising solution for rapid and accurate identification of blood types.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"28-36"},"PeriodicalIF":1.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145281034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extracorporeal photopheresis-New insights into an old procedure. 体外光切除术-对旧手术的新见解。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-06-10 DOI: 10.1111/tme.13156

Sabine Seiffert, Janine Kirchberg, Enrica Bach, Victoria Menger, Mandy Brückner, Ulrich Sack, Ulrike Köhl, Uwe Platzbecker, Andreas Boldt, Marco Herling, Vladan Vučinić

{"title":"Extracorporeal photopheresis-New insights into an old procedure.","authors":"Sabine Seiffert, Janine Kirchberg, Enrica Bach, Victoria Menger, Mandy Brückner, Ulrich Sack, Ulrike Köhl, Uwe Platzbecker, Andreas Boldt, Marco Herling, Vladan Vučinić","doi":"10.1111/tme.13156","DOIUrl":"10.1111/tme.13156","url":null,"abstract":"Background: Extracorporeal photopheresis (ECP) is a safe immunomodulatory strategy that induces cell-type selective apoptosis through photodynamic processes. Despite decades of use, the mechanisms underlying ECP remain largely unexplored, particularly in studies examining specific immune cell subsets in ex vivo setups.Aims: This proof-of-concept pilot study presents data on apoptosis and proliferation of T-lymphocytes following ex vivo ECP application to leukocyte concentrates (LC) and peripheral blood (PB) samples from healthy donors.Methods: LC and PB were diluted to a haematocrit of 2% and treated with 8-methoxypsoralen, followed by ECP (ECP+) or no ECP (ECP-) in a discontinued system. Apoptosis of mononuclear cells was assessed 48 h post-ECP using annexin V and 7 Aminoactinomycin D (7-AAD) staining with flow-cytometric quantification. The proliferative capacity of non-apoptotic T-lymphocytes was measured after 72 h of post-ECP stimulation with anti-CD3/CD28 cross-linking, using Violet Proliferation Dye 450.Results: ECP exposure significantly reduced the median T-cell receptor-induced proliferation of viable T-lymphocytes from both LC (4.6%, p = 0.02) and PB (4.2%, p = 0.03). However, 7-AAD staining 48 h post-ECP showed no significant differences in the proportions of apoptotic cells in this experimental model.Conclusion: Ex vivo ECP treatment inhibited T-lymphocyte proliferation in both LC and PB from healthy individuals, suggesting this as a key mode of action. Our findings highlight ECP's potential applications, including its implications for modern immune therapies' adverse effects. Further analyses of functional characteristics of remaining vital cells are necessary.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"53-58"},"PeriodicalIF":1.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Absence of dengue, zika and chikungunya viral nucleic acid in blood donations in China. 中国献血中未检测到登革热、寨卡病毒和基孔肯雅病毒核酸。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-11-04 DOI: 10.1111/tme.70027

Ru Xu, Ying Yan, Hui Han, Weichao Sun, Jianfeng Liang, Bin Li, Yuwei Zhao, Pincan Su, Yongshui Fu, Xia Rong, Lunan Wang

引用次数: 0

Postpartum IV iron sucrappenose, and rates of RBC transfusion: A quality improvement initiative. 产后静脉注射铁蔗糖，和RBC输血率：一个质量改进倡议。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-10-16 DOI: 10.1111/tme.70028

Itamar D Futterman, Erum Azhar, Nicole F Geller, Janet L Stein, Howard Minkoff

{"title":"Postpartum IV iron sucrappenose, and rates of RBC transfusion: A quality improvement initiative.","authors":"Itamar D Futterman, Erum Azhar, Nicole F Geller, Janet L Stein, Howard Minkoff","doi":"10.1111/tme.70028","DOIUrl":"10.1111/tme.70028","url":null,"abstract":"Background: Transfusions of packed red blood cells (RBC) have long been used to correct postpartum anaemia. Given the ongoing shortage of packed RBC and transfusion reactions, we sought to determine if the use of IV iron sucrose infusions could decrease transfusions in the postpartum period.Methods: We conducted a six-year quasi-experimental interrupted time series study from January 2016 to December 2021. The study was divided into three phases: 1. pre-intervention phase, 2. roll-out phase, and 3. post-intervention phase. Our intervention focused on a holistic transfusion prevention bundle that incorporated provider education regarding transfusion practices, antepartum optimization, and cell saver use. The main outcome was change over time from the use of IV iron sucrose over allogenic blood products in the setting of postpartum anaemia. Statistical process control (SPC) was used to explore the effect of our bundled intervention over time.Results: 46 478 deliveries were recorded. The XmR control chart showed a shift between phases 1 and 3, as indicated with a special cause signal. The U control chart demonstrated that IV iron infusions increased from 5.6 per 1000 births in phase 1 to 136.4 per 1000 births in phase 3. On Poisson regression, the rate of IV iron sucrose infusions increased 19-fold [RI 19.65 (95% CI 16.00-24.14 p < 0.0001)], while the rate of transfusions decreased by 60% [RI 0.4 (95% CI 0.33-0.49 p < 0.001)] from pre- to post-intervention.Conclusion: A holistic transfusion prevention bundle was associated with both a reduction in the number of patients transfused and the rate of multiple-unit RBC transfusions.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"37-44"},"PeriodicalIF":1.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel missense variant of the RHAG gene in the first Iraqi case of the Rh-null phenotype. 一个新的错义变异的RHAG基因在第一个伊拉克病例的Rh-null表型。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-10-01 DOI: 10.1111/tme.70029

Muqdad M N Al-Mousawi, Saad S Merza, Rozhgar A Khailany, Ali Abdulghani Ramadhan, Adil A Othman, Sanea A Ahmed, Nasir Al-Allawi

引用次数: 0

Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature. Tocilizumab为镰状细胞病高溶血综合征的治疗提供了一个潜在的治疗选择：一个病例系列和文献的简要叙述概述。

IF 1.4 4区医学

Transfusion Medicine Pub Date : 2026-02-01 Epub Date: 2025-10-09 DOI: 10.1111/tme.70026

S Wolf, B Singh, A Zaidi, P Greaves, F Oyesanya, S Bennett, B Kaya, F Barroso, P Telfer

{"title":"Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature.","authors":"S Wolf, B Singh, A Zaidi, P Greaves, F Oyesanya, S Bennett, B Kaya, F Barroso, P Telfer","doi":"10.1111/tme.70026","DOIUrl":"10.1111/tme.70026","url":null,"abstract":"Background and objectives: Hyperhaemolysis syndrome is a life-threatening complication of transfusion, potentially triggered by macrophage activation, with limited treatment options. Tocilizumab, an anti-IL6 monoclonal antibody, has mechanistic rationale for use and has been shown to be effective in a small number of cases. In this paper, we review four cases of hyperhaemolysis treated with tocilizumab in the context of the existing literature.Materials and methods: Cases of use of tocilizumab in hyperhaemolysis were identified from two large specialist haemoglobinopathy centres between the period January 2021 and March 2025. Clinical and laboratory data were collected.Results: Four cases of hyperhaemolysis treated with IVIG, steroids and tocilizumab were reported. In all cases, haemolysis responded rapidly to tocilizumab therapy. Two patients subsequently received RBC transfusions without haemolysis; two patients died from causes unrelated to haemolysis.Conclusions: This case series supports the use of tocilizumab as a therapeutic option for rapid resolution of haemolysis. It is generally widely available and should be considered a suitable and cost-effective alternative to currently available options.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"66-71"},"PeriodicalIF":1.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145259207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0